Co-Authors
This is a "connection" page, showing publications co-authored by Ioana Agache and Oliver Pfaar.
Connection Strength
2.916
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
Score: 0.932
-
COVID-19 pandemic and allergen immunotherapy-an EAACI survey. Allergy. 2021 11; 76(11):3504-3516.
Score: 0.241
-
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021 03; 76(3):689-697.
Score: 0.226
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 10; 76(10):2952-2964.
Score: 0.061
-
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy. 2021 06; 76(6):1640-1660.
Score: 0.059
-
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021 08; 76(8):2354-2366.
Score: 0.059
-
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. Int Arch Allergy Immunol. 2021; 182(4):324-338.
Score: 0.058
-
Spices to Control COVID-19 Symptoms: Yes, but Not Only…. Int Arch Allergy Immunol. 2021; 182(6):489-495.
Score: 0.057
-
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy. 2020 11; 75(11):2764-2774.
Score: 0.057
-
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 10; 75(10):2440-2444.
Score: 0.057
-
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:53-68.
Score: 0.056
-
A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020 10; 75(10):2503-2541.
Score: 0.056
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020 07; 75(7):1546-1554.
Score: 0.056
-
ARIA masterclass 2018: From guidelines to real-life implementation. Rhinology. 2019 Oct 01; 57(5):392-399.
Score: 0.053
-
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1). J Thorac Dis. 2019 Aug; 11(8):3633-3642.
Score: 0.052
-
Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol. 2019 07; 144(1):135-143.e6.
Score: 0.051
-
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy. 2019; 9:16.
Score: 0.051
-
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy. 2018 08; 73(8):1622-1631.
Score: 0.048
-
EAACI guidelines on allergen immunotherapy: Executive statement. Allergy. 2018 04; 73(4):739-743.
Score: 0.048
-
EAACI Position paper on the standardization of nasal allergen challenges. Allergy. 2018 08; 73(8):1597-1608.
Score: 0.048
-
Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. Allergy. 2018 04; 73(4):816-826.
Score: 0.047
-
Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy. 2018 04; 73(4):827-836.
Score: 0.047
-
EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018 04; 73(4):744-764.
Score: 0.047
-
EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018 04; 73(4):799-815.
Score: 0.047
-
EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018 04; 73(4):765-798.
Score: 0.046
-
EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017 Dec; 28(8):728-745.
Score: 0.046
-
Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review. Clin Transl Allergy. 2017; 7:32.
Score: 0.046
-
Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy. 2018 Jan; 73(1):64-76.
Score: 0.046
-
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy. 2018 Jan; 73(1):77-92.
Score: 0.046
-
Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clin Transl Allergy. 2017; 7:25.
Score: 0.045
-
Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017 Dec; 72(12):1825-1848.
Score: 0.045
-
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016; 6:47.
Score: 0.044
-
International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb; 137(2):358-68.
Score: 0.041